What is it about?
This study reviews the impact of Phase 4 clinical trials that followed participate for 4 years to determine the efficacy and safety of Aclidinium Bromide for individuals living with moderate to server COPD. It looked at the time to a major cardiac event and other important markers.
Featured Image
Photo by Jair Lázaro on Unsplash
Why is it important?
The use of LAMA, LABA, and ICS in various combinations has helped to provide options for individuals with difficult to control COPD. Any new medication can help to provide improved care but come with new risks that need to be considered. This review helps to consider these risks for people living with severe COPD and Cardiovascular risk factors.
Perspectives
Expanding treatment options like including Aclidinium Bromide for those with moderate to severe COPD and CV risk factors can be safe and effective.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial, Advances in Therapy, September 2021, Springer Science + Business Media,
DOI: 10.1007/s12325-021-01878-5.
You can read the full text:
Contributors
The following have contributed to this page
